CJC-1295 + Ipamorelin

CJC-1295 + Ipamorelin is the most clinically mature GH secretagogue combination available — not because it has the strongest controlled evidence base, but because it has the largest physician-supervised clinical use history of any peptide combination in this reference. Thousands of patients under medical supervision over years produced a consistent practical profile: sleep improvement within weeks, gradual body composition improvement over months, good tolerability, no HPTA suppression, and no PCT requirement. That clinical experience base is not a Phase 3 RCT. But it is real, it is large, and it is consistent.

The central tension resolved: the DAC vs no-DAC decision is the most consequential protocol choice in this chapter. CJC-1295 with DAC is convenient but produces a pharmacological profile fundamentally different from the synergistic pulse the combination is designed to create. CJC-1295 without DAC + Ipamorelin — the gold standard — preserves pulsatility, maintains receptor sensitivity, and maximizes the synergistic dual-pathway pulse that explains why the combination outperforms either compound alone. Most of the large-scale clinical prescriptions historically used the with-DAC form for compliance reasons. Most informed current practice prefers the without-DAC form for pharmacological reasons. Understanding why this distinction matters is the most important practical contribution of this chapter.

The strongest argument: the combination addresses the somatopause — the progressive age-related GH decline — through the body's own pituitary axis rather than bypassing it. It preserves the negative feedback mechanisms that prevent IGF-1 overshoot. It costs a fraction of exogenous HGH. The human clinical data on GH and IGF-1 elevation is Grade A. The clinical experience base from physician-supervised use is larger than any other peptide combination in this reference.

The strongest argument for caution: the combination has never been tested in a controlled body composition or quality-of-life trial. The benefits attributed to it — muscle gain, fat loss, sleep improvement, anti-aging — are based on GH physiology extrapolation and clinical experience, not RCT data for this specific stack. The cancer risk from chronic IGF-1 elevation in the target range is genuinely uncertain. The regulatory environment for CJC-1295 specifically (developmental drug classification) is more legally complex than other compounds in this reference. WADA explicitly bans both compounds.